Business / Finance

RSS

Aaipharma Merges With Cambridge Major Laboratories

...

3 Oct 2013

CureVac collaborates with Janssen on development of influenza vaccine based on mRNA

CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.

3 Oct 2013

Global leading supplier of pharmaceutical commercial packaging solutions, PCI, announces expansion of its personnel by 50

Packaging Coordinators, Inc. (PCI) is a global leading supplier of pharmaceutical commercial packaging solutions and clinical trials services. This week, they have announced that over the next six months the company will be further expanding its personnel by 50 at its Hay-on-Wye site. This latest recruitment drive comes after a successful apprenticeship enrolment programme, and following the placement of four Undergraduates from Swansea University; reinforcing the company’s commitment to supporting the development and education of the local community. Since April 2013, PCI has already recruited 40 staff members within the life sciences sector, signaling itself as one of the principal employers within the Life Sciences/Biotech industry in Wales.

From Packaging Coordinators Inc. (PCI) 3 Oct 2013

CaringBridge signs strategic agreement with Hallmark Cards

CaringBridge, a nonprofit social network that keeps families and loved ones connected during any type of health event, today announced a strategic agreement with Hallmark Cards, Inc., the world's leading greeting card brand. Through the collaboration, the two organizations will create co-branded content, product and services that will combine the two brands' insights and expertise to help people.

2 Oct 2013

NIMH Awards Optivia $1.8M CNS Drug Development

...

2 Oct 2013

Servier Joins Xention To Develop AF Drug In Up To $163.2M Deal

...

2 Oct 2013

Moderna Therapeutics Scores Up To $25M DARPA Grant

...

2 Oct 2013

Sofie Bio Seeks To Speed PET Probe Synthesis With SBIR Grant

...

2 Oct 2013

Acino Supports Acquisition By Private Equity Firms

...

2 Oct 2013

WATCH: The Novex Bolt Orchestra

...

1 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

...

1 Oct 2013

Lundbeck Cutting 180-200 Jobs In Business Services Overhaul

...

1 Oct 2013

Lundbeck Cutting 180-200 Jobs In Business Services Overhaul

...

1 Oct 2013

FDA Approves Takeda-Lundbeck Drug For Major Depressive Disorder

...

1 Oct 2013

Merck & Co. Axes 8,500 In R&D Restructuring

...

1 Oct 2013

Sun Pharma, Intrexon partner to develop controllable gene-based therapies for ocular diseases

Sun Pharmaceutical Industries Ltd., an international specialty pharmaceutical company focused on chronic diseases, through its subsidiary, and Intrexon Corporation, a leader in synthetic biology, today announced the formation of a joint venture to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide.

1 Oct 2013

MiMedx Group enters into distribution agreement with Medtronic and SpinalGraft Technologies

MiMedx Group, Inc., an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has entered into a distribution agreement with Medtronic, Inc. and SpinalGraft Technologies, LLC, a wholly-owned subsidiary of Medtronic.

From Medtronic 1 Oct 2013